Ixaka France, S.A. – Trademark Portfolio

Entity Type: 98

Ixaka France, S.A. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 5 Nice Classification classes.

Villejuif Bio Park,

1 Mail du Professeur Georges Mathé F-94800 Villejuif

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

IXACTILE
IXACTILE
Abandoned 2022

Trademark Classifications

Ixaka France, S.A.'s trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

40
Treatment & Processing (1 filing)

Treatment of materials

Frequently Asked Questions

How many trademarks does Ixaka France, S.A. have?

Ixaka France, S.A. has 1 U.S. trademark filed with the USPTO.

What trademark classes does Ixaka France, S.A. file in?

Ixaka France, S.A. files trademarks across 5 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What is Ixaka France, S.A.'s trademark registration success rate?

Ixaka France, S.A. has a 0% trademark registration rate, with 0 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.